The deal is the result of restructuring a collaboration, which began in 2020 to develop mRNA-based vaccines for infectious diseases, into a new licensing agreement, GSK added. As a result of the collaboration, the two companies have vaccine candidates for seasonal influenza and COVID-19 in phase II clinical development and avian influenza in phase I clinical development.
During President Donald Trump’s second term, congressional Republicans have both become simultaneously less moderate and less likely to embrace limited...
Trump was right to strike Iran, but an unfinished war risks letting the regime rebuild. Six measures are outlined to neutralize the threat and prevent renewed escalation....